Helicobacter pylori and Pro-Inflammatory Protein Biomarkers in Myocardial Infarction with and without Obstructive Coronary Artery Disease
- PMID: 37762446
- PMCID: PMC10531769
- DOI: 10.3390/ijms241814143
Helicobacter pylori and Pro-Inflammatory Protein Biomarkers in Myocardial Infarction with and without Obstructive Coronary Artery Disease
Abstract
Myocardial infarction (MI) with obstructive coronary artery disease (MI-CAD) and MI in the absence of obstructive coronary artery disease (MINOCA) affect different populations and may have separate pathophysiological mechanisms, with greater inflammatory activity in MINOCA compared to MI-CAD. Helicobacter pylori (Hp) can cause systemic inflammation and has been associated with cardiovascular disease (CVD). We aimed to investigate whether Hp infection is associated with concentrations of protein biomarkers of inflammation and CVD. In a case-control study, patients with MINOCA (n = 99) in Sweden were included, complemented by matched subjects with MI-CAD (n = 99) and controls (n = 100). Protein biomarkers were measured with a proximity extension assay in plasma samples collected 3 months after MI. The seroprevalence of Hp and cytotoxin-associated gene A (CagA) was determined using ELISA. The associations between protein levels and Hp status were studied with linear regression. The prevalence of Hp was 20.2%, 19.2%, and 16.0% for MINOCA, MI-CAD, and controls, respectively (p = 0.73). Seven proteins were associated with Hp in an adjusted model: tissue plasminogen activator (tPA), interleukin-6 (IL-6), myeloperoxidase (MPO), TNF-related activation-induced cytokine (TRANCE), pappalysin-1 (PAPPA), soluble urokinase plasminogen activator receptor (suPAR), and P-selectin glycoprotein ligand 1 (PSGL-1). Hp infection was present in one in five patients with MI, irrespective of the presence of obstructive CAD. Inflammatory proteins were elevated in Hp-positive subjects, thus not ruling out that Hp may promote an inflammatory response and potentially contribute to the development of CVD.
Keywords: Helicobacter pylori; MINOCA; biomarkers; coronary artery disease; inflammation; myocardial infarction.
Conflict of interest statement
Jonas Spaak declares speaker honoraria from AstraZeneca, Bayer, and Medtronics, all outside the current work. The remaining authors have nothing to disclose. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
Figures
Similar articles
-
Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.Clin Chem. 2019 Aug;65(8):1023-1030. doi: 10.1373/clinchem.2018.301085. Epub 2019 May 9. Clin Chem. 2019. PMID: 31072836
-
Pro-Inflammatory Biomarkers and Progression of Atherosclerosis in Patients with Myocardial Infarction with Non-Obstructive Coronary Artery Disease: 1-Year Follow-Up.J Pers Med. 2023 Nov 29;13(12):1669. doi: 10.3390/jpm13121669. J Pers Med. 2023. PMID: 38138896 Free PMC article.
-
Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.J Physiol Pharmacol. 2001 Aug;52(1 Suppl 1):3-31. J Physiol Pharmacol. 2001. PMID: 11795863 Clinical Trial.
-
Do Patients with Myocardial Infarction with Non-Obstructive Coronary Arteries Have Similar Prognosis Compared to Ones with MI-CAD?Angiology. 2023 May;74(5):407-416. doi: 10.1177/00033197221121191. Epub 2022 Aug 22. Angiology. 2023. PMID: 35993693 Review.
-
Myocardial Infarction with Nonobstructive Coronary Arteries.Annu Rev Med. 2023 Jan 27;74:171-188. doi: 10.1146/annurev-med-042921-111727. Epub 2022 Sep 30. Annu Rev Med. 2023. PMID: 36179347 Review.
Cited by
-
The influence of Helicobacter pylori infection on acute coronary syndrome and lipid metabolism in the Chinese ethnicity.Front Cell Infect Microbiol. 2024 Sep 3;14:1437425. doi: 10.3389/fcimb.2024.1437425. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39290976 Free PMC article.
References
-
- Tamis-Holland J.E., Jneid H., Reynolds H.R., Agewall S., Brilakis E.S., Brown T.M., Lerman A., Cushman M., Kumbhani D.J., Arslanian-Engoren C., et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139:e891–e908. doi: 10.1161/CIR.0000000000000670. - DOI - PubMed
-
- Pelliccia F., Pasceri V., Niccoli G., Tanzilli G., Speciale G., Gaudio C., Crea F., Camici P.G. Predictors of Mortality in Myocardial Infarction and Nonobstructed Coronary Arteries: A Systematic Review and Meta-Regression. Am. J. Med. 2020;133:73–83.e4. doi: 10.1016/j.amjmed.2019.05.048. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous